Q3 2024 Earnings Call Transcript November 5, 2024 Apellis Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.46 EPS, expectations were $-0.32. Operator: Good morning, ladies ...

Apellis Pharmaceuticals Inc (APLS) reports significant revenue growth but faces market and regulatory hurdles in Q3 2024.

Apellis Pharmaceuticals (APLS) stock falls as company's Q3 2024 financials disappoint with lower-than-expected U.S. sales ...

Generated $196.8 million in 3Q 2024 revenues, including $176.6 million in U.S. net product salesGrew SYFOVRE® (pegcetacoplan injection) demand by ...

Shares of Apellis Pharmaceuticals have been under pressure because investors are concerned about the sales trajectory of its vision preservation treatment, Syfovre. Although Syfovre has been ...

Apellis Pharmaceuticals is marketing Syfovre, a new treatment for patients with a leading cause of blindness. Syfovre is approved in the U.S., but Apellis' stock tanked after European regulators ...

Four months after the Committee for Medicinal Products for Human Use (CHMP) rejected Apellis’ GA application for Syfovre for a second time, Astellas has withdrawn its application for the ...

Pegcetacoplan is already approved in paroxysmal nocturnal hemoglobinuria (PNH) and geographic atrophy (GA) under the brand names Empaveli and Syfovre, respectively. Two days after Apellis’ data ...

The Committee for Medicinal Products for Human Use (CHMP) has recommended that the drug be used in combination with an aromatase inhibitor as an adjuvant treatment for adults with hormone receptor (HR ...

Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, because that oh-so familiar routine of deadlines, online calls, and meetings ...

In February, the CHMP said it was minded to reject Orphazyme's application for arimoclomol, intended as a treatment for a third type of ASMD – Niemann-Pick disease type C – saying it would ...